Trump’s US price policy aims to remove barriers

Ending the “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies”, advancing biosimilars and generics to encourage greater competition and offering free generics to low-income seniors are among the measures set out in a “blueprint to lower drug prices” that has just been announced by US President Donald Trump. Billing the reform as “the most sweeping action in history to lower the price of prescription drugs for the American people”, Trump said his administration would be “eliminating the middlemen” and targeting ‘freeloading’ other countries.